CRISPR Therapeutics is led by a seasoned management team focused on translating CRISPR/Cas9 technology into transformative gene-based medicines for patients with serious diseases. We are working in parallel with our world-class group of scientific founders and advisors, who have extensive experience in gene editing, stem cell biology, advanced drug delivery technologies, RNAi and gene silencing.
Dr. Rodger Novak co-founded CRISPR Therapeutics together with Emmanuelle Charpentier and Shaun Foy. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. He brings a combination of scientific experience, gained through his academic career, and a proven track record of successfully translating technologies into pharmaceutical products.
In his most recent position, Rodger was Global Head, Anti-Infectives Research & Development at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmceutical career at Sandoz (Novartis), where he was appointed as the deputy Head of the Antibiotic Research Institute.
Rodger received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the U.S. in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. During his academic career Rodger authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. Rodger is co-inventor of five patents.
Dr. Bill Lundberg has extensive experience across all aspects and phases of drug development in both academic and industry settings. He was previously Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he was responsible for all R&D from discovery to clinical proof-of-concept. Before that, Bill held senior positions at Taligen Therapeutics, Antisoma, Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme, overseeing the development of diverse portfolios.
Bill received his B.S. in biology from the Massachusetts Institute of Technology (MIT), M.D. from Stanford Medical School and M.B.A. from the University of Massachusetts Amherst. As a post-doctoral fellow he studied at the Whitehead Institute at MIT, and trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Dr. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, Sam co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications.
Sam received his Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in numerous leading journals.
Marc Becker has more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry. He was previously Chief Financial Officer and Senior Vice President of rEVO Biologics, where he led the finance team in anticipation of raising private and public capital, outlined the market opportunity for the Company and managed its governance and SEC Compliance through S-1 filing and IPO road show.
Before that, Marc spent 10 years at Genzyme, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for the Renal and Endocrine business. He held global P&L responsibility with multiple product lines, large scale, and reimbursement complexity.
Marc started his career in auditing and commercial lending for financial services firms, KPMG and BankBoston, and holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.
Dr. Tyler Dylan-Hyde has more than two decades of experience both in law firms and in-house for privately-held and public companies developing gene-based therapeutics and other technologies.
Tyler was a Partner at Morrison & Foerster LLP, specializing in the development and defense of global IP portfolios, licensing and corporate transactions. As in-house general counsel, he helped lead Collateral Therapeutics, which had an IPO on NASDAQ and was later acquired by Schering AG (now Bayer Healthcare Pharmaceuticals), InnerCool Therapies, which was advanced through FDA clearance and acquired by Philips Healthcare, and Cardium Therapeutics, which developed a portfolio of companies, some acquired and others currently in partnership.
Tyler received his B.Sc. in cell, molecular and developmental biology from McGill University, Montreal, Canada, his Ph.D. in biology from the University of California, San Diego, and his J.D. from the University of California, Berkley (Boalt Hall School of Law). He is a co-inventor of several patent applications and a co-author of a number of scientific publications.
Dr. Kala Subramanian has extensive experience in Strategic Planning, Portfolio and Program management across early and late stage development in Oncology and other therapeutic areas. In her most recent position, Kala was Vice President and Global Head of Strategic Development & Program Management at Novartis Pharmaceuticals (Oncology), where she was responsible for program and portfolio management, strategic planning, resource allocation and management of budget. She was also responsible for the integration of GSK Oncology into Novartis including full alignment of the portfolio, organization & people. Before that, Kala was in program management at Millennium and a senior consultant at Accenture.
Kala received her PhD in Physical Chemistry from Cornell University and was a post-doctoral fellow at Duke University Medical Center.
Dr. Chad Cowan is an Associate Professor at Harvard University in the Department of Stem Cell and Regenerative Biology, and at Massachusetts General Hospital, with appointments in the Center for Regenerative Medicine, the Cardiovascular Research Center and the Center for Human Genetics Research. He is an associate member of the Broad Institute and a principal faculty member of the Harvard Stem Cell Institute, where he directs the Diabetes Disease Program and the iPS Cell Core Facility.
Chad has led or been a member of several large efforts to use stem cells to better understand disease, including the National Heart, Lung, and Blood Institute’s Next Gen iPS Cell Project and the Progenitor Cell Biology Consortium. More recently, Chad has focused on using gene editing tools as therapeutics.
Chad received his B.A. and B.S., with honors, from the University of Kansas. He received his Ph.D. from the University of Texas Southwestern at Dallas, garnering the Nominata award for most outstanding thesis. He subsequently completed a Damon Runyon fellowship with Professor Douglas Melton at Harvard University. He was named a Stowers Medical Investigator in 2006 and has been a faculty member at Harvard University since 2008.
Megan brings extensive HR experience from the pharmaceutical, biotech and life science industries having worked at organizations including Novartis, Amgen and Bristol Myers-Squibb. Most recently, she spent 8 years with Merck KGaA in roles with increasing responsibility. She served as VP and Head of HR for EMD Serono, where she was responsible for all HR functions including HR Business Partners, Talent Acquisition, Talent Development, Compensation, Benefits & Payroll as well as HR Metrics and Operations for the US Pharmaceutical Business. In her next role, Megan was VP and Head of HR International where she was responsible for the entire HR organization of 900 team members in 60+ countries and created the first truly global HR organization working with all businesses at the company. Megan also served as VP and Head of HR for the Chemicals Sector having full strategic HR responsibility for the Life Science and Performance Materials divisions. In her last role at the company, Megan was VP and Head of HR for the global Merck Millipore Life Science business and led the people and organizational integration of the Sigma-Aldrich acquisition.
Dr. Jon Terrett has an extensive track record for discovering and progressing immuno-oncology drug candidates into the clinic. Prior to joining CRISPR Therapeutics, Jon was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, Jon has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences.
Jon received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.